Health

STAT+: Sanofi avoids fine as EU accepts offer to end antitrust probe over disparaging rival vaccine

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 14/10/2026, 12:27:27 UTC.

Briefings

The European Commission accepted a settlement with Sanofi to avoid a fine after the company agreed to rectify an alleged misleading campaign disparaging its Efluelda vaccine compared to the rival Fluad. Teresa Riberta, the European Commission executive vice president for Clean, Just and Competitive Transition, confirmed the agreement is legally binding. The probe focused on communications targeting healthcare professionals in Germany and France, where Sanofi holds a dominant market position.

Key points

• Sanofi avoided a potential fine by agreeing to a corrective communication campaign to rectify alleged disparaging behavior toward its Efluelda vaccine.
• The European Commission executive vice president Teresa Riberta confirmed the settlement is legally binding and requires Sanofi to refrain from such behavior in the future.

Context and limitations

The evidence covers only the EU antitrust investigation into a campaign disparaging the Fluad vaccine in Germany and France. It does not include data on the full scope of the campaign, specific numbers of affected professionals, or the timeline of the investigation beyond the 2026 publication date.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 14/10/2026, 13:23:35 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifvrlh7dwzijs2irsqapnrh4xmfcfj3e2mahojb6zyivqzobgtxda